Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
FIT-003 by Guangzhou FineImmune Biotechnology for Solid Tumor: Likelihood of Approval
FIT-003 is under clinical development by Guangzhou FineImmune Biotechnology and currently in Phase I for Solid Tumor. According to GlobalData,...